Roche sev­ers ties with 4D Mol­e­c­u­lar Ther­a­peu­tics over blind­ness gene ther­a­py, mark­ing an­oth­er set­back for the field

Roche is turn­ing its nose up over a gene ther­a­py pro­gram tar­get­ing an in­her­it­ed form of night blind­ness, sig­nal­ing the lat­est set­back for such treat­ments in eye-re­lat­ed dis­eases.

As the space con­tin­ues to reel from Bio­gen’s ma­jor Phase III flop last week, Roche is hand­ing back rights to a pro­gram from 4D Mol­e­c­u­lar Ther­a­peu­tics, the biotech an­nounced Thurs­day morn­ing. The ter­mi­na­tion of the li­cens­ing agree­ment will be ef­fec­tive as of Sept. 16, 4DMT said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER